Cnbx Pharmaceuticals INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OID
CNBX Pharmaceuticals Inc. has dismissed its independent registered public accounting firm, Elkana Amitai CPA, and appointed Vilki & Luxor Palace as its new auditor, a move occurring despite no stated disagreements with the former firm.
OID
CNBX Pharmaceuticals Inc. has secured a $45,000 non-convertible promissory note from 3i L.P. to fund immediate working capital needs, incurring a 20% premium on all repayments.
OID
CNBX Pharmaceuticals entered into a convertible promissory note agreement for an immediate $55,000 and potential additional funding up to $850,000.
OID
CNBX Pharmaceuticals has replaced its independent auditor, Weinstein International CPA, with Elkana Amitai, CPA, effective March 18, 2024.